Oramed has transformed into an asset-rich biomedical holding company trading below the value of its investments while retaining free upside from oral insulin, medical robotics, oncology, and royalty streams.
Overview
Oramed is now a diversified biomedical holding company with a proprietary oral protein-delivery platform, valuable strategic stakes in Alpha Tau and Lifeward, secured notes from Scilex and Lifeward, and future royalty streams. The March 2026 Lifeward transaction shifted clinical-trial funding away from Oramed, reducing cash burn while retaining upside in oral insulin. With roughly $220.5 million in assets, zero debt, and shareholder dividends, the company offers a rare blend of biotech optionality, asset-backed downside protection, and capital-allocation discipline.